Genmab Stock Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
Sales 2024 * | 19.66B 2.82B | Sales 2025 * | 23.51B 3.37B | Capitalization | 127B 18.18B |
---|---|---|---|---|---|
Net income 2024 * | 5.11B 732M | Net income 2025 * | 6.76B 969M | EV / Sales 2024 * | 5.1 x |
Net cash position 2024 * | 26.57B 3.81B | Net cash position 2025 * | 33.5B 4.8B | EV / Sales 2025 * | 3.97 x |
P/E ratio 2024 * |
25
x | P/E ratio 2025 * |
19.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
Latest transcript on Genmab
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 98-12-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 06-12-31 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 20-03-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 16-12-31 |
Director/Board Member | 73 | 03-10-31 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 15-12-31 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B | |
-24.71% | 8.08B |